Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Wellcome Trust
Wellcome Trust
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Oxford clinical trial for COVID-19 treatments expands internationally
The international trial will initially focus on the treatments aspirin and colchicine, since these are readily available and affordable
Research & Development
Study demonstrates way to target hard-to-treat cancer mutation
The study was funded by Cancer Research UK and Wellcome
Research & Development
Collaborators use CRISPR to catch cancer-causing gene fusions
A team from the Wellcome Sanger Institute and collaborators have identified a new gene fusion that presents a novel drug target for multiple cancers, including brain and ovarian
Finance
Karuna completes $42 million financing round
Participants include ARCH Venture Partners, Wellcome Trust, PureTech Health, Steven Paul MD, and other undisclosed investors
Hi Tech Manufacturing
£10m research competition to tackle antimicrobial resistance
Move aims to encourage the development of innovative scientific approaches to addressing antimicrobial resistance
Regulatory
Karuna receives $8m Wellcome Trust award
The funding will be used to advance the company's lead product candidate, KarXT, through a Phase II study in people with schizophrenia
Research & Development
Polyphor and Wellcome Trust to develop novel antibiotics against multi-drug resistant Gram-negative pathogens
Final milestone reached ahead of schedule triggering payment of a CHF 0.97 million convertible loan amount
Subscribe now